The company has spoken of a new global trial to deal with the situation of criticism and confusion over the results of the trial of AstraZeneca's COVID vaccine. The company's CEO Pascal Sorriot has said that the company wants to conduct a new trial to confirm the 90% effectiveness rate seen in the current trial.

The company claimed that giving half the dose of the vaccine proved more effective, since then there have been constant questions about the vaccine. The pharmaceutical company and partner Oxford University did not initially reveal the shortcomings and other information, leading to questions on the transparency of the vaccine. Soriot said that if we have recorded the proper efficacy of the vaccine, then we have to validate it. For this, we have to do another trial. This trial will also be at international level, but it is expected to take less time because we know the effectiveness of the vaccine so we will need less number of patients.

The trial of the vaccine led to AstraZeneca and Oxford confessing that there was an error in the vaccine dose, leading to 90 percent effectiveness. Thereafter, questions are arising over the data related to the effect of the vaccine. Scientists believe that people have lost faith in the vaccine's impact after a company error.

Also Read:

Maradona funeral suspended as massive mourners force to enter govt palace

Farmers Allowed To Enter Delhi, Police To Escort Them

Governor says Sao Paulo may make use of Sinovac vaccine after trail